Chimeric antigen receptors (CARs) are synthetic T cell receptors used to re-direct T cell effector functions toward tumor associated antigens (TAAs). 1, 2 Commonly consisting of a TAAspecific antibody single chain variable fragment (scFv) fused via a spacer and transmembrane domain to intracellular T cell signaling domains, when a CAR binds to its target antigen, T cell signaling is initiated leading to target cell lysis, cytokine production and cell proliferation. 3 Clinical trials with adoptively transferred CAR T cells targeting the B cell antigen CD19 have been highly successful in treating refractory acute lymphoblastic leukemia, and there is much interest in expanding the antigens targeted by CARs and the number of cancers that can be treated. 1, [4] [5] [6] [7] Despite this success and interest, many challenges remain to expanding the application of CAR therapy. The single antigen specificity of CARs can render them ineffective against tumors that lack expression of the target antigen due to antigen loss or tumor heterogeneity. 8 Additionally, the unregulated persistence of CAR activity can cause cytokine release syndrome and other toxicities. 9 For targeting new cancers, the creation of new CARs is needed, which is technically challenging and requires extensive engineering and safety testing to rule out off-tumor toxicities. 10 One alternative approach that addresses some of these challenges is the creation of CARs that bind to common tag molecules -such as fluorescein isothiocyanate (FITC), peptide neo-epitopes (PNE), Fcg, and biotin -that are conjugated to TAA-specific antibodies. [11] [12] [13] [14] So-called anti-tag CAR (AT-CAR) therapy would be designed so that patients are infused with a tagged, TAA-specific antibody that binds to tumor cells, followed by T cells expressing AT-CARs that react with the tagged antibodies on tumor cells (Fig. 1A) . This approach has the potential to allow for sequential or simultaneous targeting of multiple tumor antigens with different antibodies. 15 Additionally, the activity of AT-CARs can be regulated by altering the concentration of tagged antibodies or halting antibody administration for better control over potential toxicities. 16 Here we report the construction and characterization of a new AT-CAR with potent activity composed of the affinityenhanced monomeric streptavidin (mSA2) protein, engineered to have high affinity for biotin compared to other monomeric and dimeric avidins (K d D 5.5 £ 10 ¡9 at 37 C). 17 Previous studies have shown that higher affinity can lead to greater T cell activation and antitumor response in the AT-CAR format. 16 We find that mSA2 CAR T cells are efficiently stimulated by plate-immobilized biotin and that they are capable of potent target cell lysis and cytokine production when combined with biotinylated TAA-specific antibodies.
We first constructed lentiviral vectors encoding two mSA2 CAR signaling domain variants, mSA2-41BBz and mSA2-CD28z (Fig. 1B) . Driven by the EF1a promoter, CAR-coding regions consisted of the murine Igk leader sequence, the codonoptimized mSA2 protein domain, the CD8a-hinge spacer domain, the CD28 transmembrane domain, either the CD28 or the 4-1BB cytoplasmic domain and the CD3z cytoplasmic domain. Additionally, to mark transduced cells, we added the TagBFP marker gene via a T2A co-translation peptide. 18 An anti-CD19 CAR, FMC63-CD28z, which consisted of the FMC63 scFv, the IgG4 extracellular spacer, CD28 transmembrane and co-signaling domains and CD3z, was also constructed as a positive control CAR. 19 All the vectors were packaged into lentiviruses and transduced into primary human T cells.
We found that the mSA2 CARs were efficiently expressed on the cell surface (Fig 2A) and that the mSA2 CAR T cells could be activated by plate-bound biotin (Fig 2B) . Following one stimulation cycle, transduced T cells were sorted for TagBFP expression and then stained with biotin-FITC. The staining with biotin-FITC was specific to mSA2 CAR T cells and correlated with TagBFP expression (Fig. 2A) . T cells were also evaluated for helper and cytotoxic populations based on CD4 and CD8 expression. Next, we found that the mSA2 CAR T cells could be efficiently activated by plate-immobilized biotin (Fig. 2B) . Specifically, we incubated CAR T cells or control cells on plates coated with biotinylated antibodies for 18 hours and then assayed cells for T cell activation markers by flow cytometry. Incubation with plate immobilized biotin led to the upregulation of T cell activation markers CD69 and CD107 a as well as the downregulation of CD62 L. We found that FMC63-CD28z CAR T cells were activated by the plate immobilized anti-hIgG4 antibody that can bind to the IgG4 extracellular spacer but not by a biotinylated antibody against an irrelevant target (anti-MUC1 antibody H15K6).
Next, we tested if mSA2 CAR T cells could be combined with anti-tumor antibodies to mediate specific T cell effector functions. We co-incubated mSA2-41BBz or mSA2-CD28z T cells with CD20C Raji target cells (Fig. S1 ) in the presence of varying amounts of biotinylated Rituximab (anti-CD20). The mSA2 CAR T cells responded by up-regulating T cell activation markers in a dose-responsive manner to the biotinylated Rituximab (Fig. 3A) . They also produced IFNg (Fig. 3B ) and performed target cell lysis (Fig. 3C ) in a dose-responsive manner. We found that mSA2-CD28z T cells produced vastly more IFNg compared to the mSA2-41BBz T cells, however, both showed comparable levels of specific target cell lysis. This result is consistent with previous findings for traditional CARs with CD28 versus 4-1BB co-signaling domains from several research groups. [20] [21] [22] [23] It is likely the result of established differences in CD28 and 4-1BB signaling pathways which signal via Akt and TRAFs, respectively. 21, 24 Notably, incubating the mSA2 CAR T cells with biotinylated antibody and off-target cells lead neither to T cell activation nor any significant induction of T cell effector functions, indicating that immobilizing the antibodies on the surface of the target cells was necessary to initiate CAR T cell receptor signaling and that soluble antibody alone could not induce activation. As an additional control, we found that MOCK transduced T cells, when combined with biotinylated antibodies, were not activated nor induced to produce cytokines or lyse tumor cells (Fig. S2) .
We then tested the activity of mSA2-41BBz and mSA2-CD28z CAR T cells when combined with various antigen-positive and antigen-negative target cell lines, in the presence of biotinylated Rituximab, FMC63 (anti-CD19), or biotinylated Cetuximab (anti-EGFR) antibodies. Biotinylated Cetuximab served as a negative control as its target antigen, EGFR, is not expressed on any of the targeted cell lines. Target cell lines included Jurkat cells which are negative for both CD19 and CD20, K562 cells which are negative for both CD19 and CD20, K562 cells which are engineered to express CD19 (K562CCD19), and Raji cells which are naturally positive for both CD19 and CD20 (Fig. S1) . Following co-incubation of T cells and target cells with the different biotinylated antibodies, we found that the mSA2-CAR T cells were induced to express activation markers (Fig. 4A) , produce IFNg (Fig. 4B ) and lyse target cells (Fig. 4C) . Importantly, the presence of both the biotinylated antibody and the targeted antigen on the cancer cells was required for mSA2 CAR cells to be activated and functional. We found that the lytic abilities of mSA2-CD28z CAR cells were comparable to the FMC63-CD28z positive control CAR.
Future studies will include in vivo testing of mSA2-41BBz and mSA2-CD28z CAR T cells in mice bearing human tumor xenografts with different biotinylated antibody doses and schedules. The potency of the biotinylated antibodies and mSA2 CAR T cells could potentially be further improved by performing sitespecific biotinylation on the antibodies at various amino acid positions and selecting for sites that give the most potent lysis, likely optimizing the formation of the T cell synapse. 16 For future therapeutic applications one concern is the potential immunogenicity of the mSA2 protein. While it is known that tetrameric avidin can elicit antibody and cellular responses, additional studies will be necessary to determine immunogenicity of the monomeric mSA2. 25 The monomeric form with fewer repeating structures could be expected to elicit a more diminished antibody response. Nevertheless, mutations have been reported that can make tetrameric avidin less immunogenic, which could be applied to the mSA2 protein domain. 26 As many CARs in the clinic have immunogenic mouse antibody domains including the most common CAR FMC63, there could be a similar therapeutic window in which the mSA2-CAR T cells could function before being rejected. In comparison to other tag-CARs, the biotin tag may be better tolerated than PNE or FITC, which are entirely foreign molecules.
The mSA2-CAR is a new AT-CAR with potential for targeting several different antigens by T cells engineered to express a single CAR. Complementary to previously developed tagCARs, the mSA2 avidin binding domain has a unique compact structure (122 amino acids in length) that may make it suitable to targeting particular new antigens. This CAR has great promise for use in combination with the ever-increasing list of FDAapproved tumor-targeting antibodies and antibodies in clinical development. 7 It is also ripe for combining with antibodies that display tumor-specificity but lack anti-tumor therapeutic activities on their own. In addition to future promise as an off-theshelf therapeutic, which will be tested in preclinical animal models, the mSA2-CAR can already be used as an off-the-shelf reagent for preselecting in vitro the best candidate antibodies for antigen binding domains of traditional CARs before proceeding with their construction.
Materials and methods

Lentiviral vector construction and virus production
The CAR coding regions listed in Supplementary Table S1. were synthesized (Integrated DNA Technologies) and cloned into the pSICO-EF1 vector using Gibson Assembly. 18 Virus was generated using the above described transfer vectors following methods described previously in detail. 18 
Antibody biotinylation
Antibodies FMC63, Rituximab and Cetuximab were purchased (Absolute Antibody) and biotinylated using the EZ-Link NHS biotin kit (ThermoFisher Scientific) and were determined by HABA assay to contain an average of 3-4 molecules of biotin per antibody.
Cell line culture
Human tumor cell lines Jurkat Clone E6-1 (TIB-152), K562 (CCL-243), and Raji (CCL-86) were obtained from American Type Culture Collection (ATCC) and cultured at 37 C in RPMI medium supplemented with 1X MEM amino acids solution, 10 mM Sodium Pyruvate, 10% fetal bovine serum (FBS) and Penicillin-Streptomycin (Life Technologies). K562CCD19 cells that stably express full-length CD19 were generated by transducing K562 cells with CD19-expressing lentivirus and sorting for cells positive for CD19 expression. HEK293 T (human embryonic kidney) cells (ATCC) were cultured at 37 C in DMEM supplemented with 10% FBS, and PenicillinStreptomycin.
Primary human T cell culture and lentiviral transduction
All experiments were performed on PBMC isolated from deidentified human Buffy Coat samples purchased from the Pittsburgh Central Blood Bank fulfilling the basic exempt criteria 45 CFR 46.101(b)(4) in accordance with the University of Pittsburgh IRB guidelines. Human T cells were cultured in supplemented RPMI media as described for cell lines above, however, 10% Human AB serum (Gemini Bio Products) was used instead of FBS, and the media was further supplemented with 100 U/ml human IL-2 IS and 1 ng/ml IL-15 (Miltenyi Biotec). PBMC were isolated from a Buffy Coat from healthy volunteer donors using Ficoll centrifugation and total human T cells were isolated using the Human Pan T cell isolation kit (Miltenyi Biotec). T cells were stimulated and expanded using TransAct Human T cell Activation Reagent (Miltenyi Biotec). For transduction, two days after addition of TransAct, lentivirus was added to cells at an MOI of 10-50 in the presence of 6 mg/ml of DEAE-dextran (Sigma Aldrich). After 18 hours, cells were washed and resuspended in fresh T cell media containing 100 U/ml IL-2 and 1 ng/ml IL-15. After an additional 12 days of stimulation and expansion, CARCcells were flow-sorted by TagBFP expression. To obtain sufficient numbers of cells for experiments, sorted CARC cells then underwent an additional TransAct stimulation cycle prior to being assayed.
Flow cytometry staining
Cells were stained using the indicated antibodies and diluted in flow cytometry buffer (PBS C 2% FBS), for 30 minutes at 4 C followed by two washes with flow cytometry buffer. Live cells were gated based on forward and side scatter and CARC cells were gated on TagBFP expression. 50,000 total events were recorded per sample.
Plate-immobilized biotin stimulation assay
High protein-binding 96 well flat-bottom plates (Corning) were coated with 10 mg/ml of biotinylated antibody in PBS or with PBS alone for 2 hours at 37 C and washed 2 times with PBS. 100,000 CAR T cells were incubated on the plate for 18 hours. After incubation, cells were stained with antibodies against T cell activation markers CD69-PE (BD Biosciences), CD62L-FITC (BD Biosciences) and CD107a-APC (BD Biosciences) and evaluated for marker expression by flow cytometry.
CAR T cell and target cell antibody-mediated activation co-incubation assay 100,000 primary T cells were co-cultured with 10,000 target cells and the indicated amounts of biotinylated antibodies for 18 hours. After incubation, cells were stained with antibodies against T cell activation markers CD69-PE (BD Biosciences) and CD62L-FITC (BD Biosciences) and evaluated for activation marker expression by flow cytometry. Supernatants from these co-cultures were also collected and analyzed for the presence of IFNɣ by ELISA (BioLegend). Assays were performed in triplicate and average IFNɣ production was plotted with standard deviation.
Target cell lysis assay
Target cells were stained with Cell Trace Yellow following manufacturer's recommendation (ThermoFisher), re-suspended in DMEM-media and plated at 10,000 cells per well in 50 ml in a 96 well V-bottom plate. 50 mL of CAR T cells were added at E: T ratio of 10:1 (100,000 effector cells). Plates underwent a quick spin to collect cells at the bottom of the wells and were incubated at 37 C for 18 hours. To identify lysed cells, samples were stained with Ghost Dye Red Viability Dye (Tonbo Biosciences) and analyzed by flow cytometry. Target cells were identified by Cell Trace Yellow and lysed target cells were identified by positive Ghost Dye staining. Specific cytotoxicity was calculated by the equation: 100 Ã (% experimental lysis -% target-only lysis) / (100 -% target-only lysis).
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